fda tirzepatide announcement says that the GLP-1 shortage is over Today the FDA issued its

Semaglutide CVOT, SUSTAIN-6 Visual Abstract as a GIF In fact, Novo Nordisk used data like these to gain a new indication for semaglutide just last week: Today, the [FDA] approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight

together these effects reduce caloric intake and shift substrate utilization toward increased fat oxidation

Tirzepatides dual-action mechanism may provide better metabolic benefits than Semaglutide

2 shows a practical algorithm for regimen start and adjustment